Back to resultsPhase I Study of the HS-10352 in Patients With Advanced Breast Cancer
Primary Purpose
Breast Cancer
Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
HS-10352
Sponsored by
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring dose-escalation, advanced solid tumors, estrogen receptor positive breast cancer, PIK3CA gene mutation
Eligibility Criteria
Inclusion Criteria:
- Men or women aged more than or equal to (≥) 18 years, and less than (<) 75 years.
- HR+ HER2- locally advanced or metastatic breast cancer patients confirmed by histology or cytology for who that standard treatment is invalid, unavailable or intolerable.
- Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: measurable lesions without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter ≥ 10 mm in the baseline period (in case of lymph nodes, the shortest axis ≥ 15 mm is required)
- ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks.
- Estimated life expectancy greater than (>) three months.
- Females should be using adequate contraceptive measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have evidence of non-childbearing potential.
- Sign Informed Consent Form.
Exclusion Criteria:
Treatment with any of the following:
- Previous or current treatment with PI3K, AKT or mTOR inhibitors.
- Any cytotoxic chemotherapy, investigational agents within 21 days of the first dose of study drug; anticancer drugs which have been received within 14 days before the first administration.
- Radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.
- Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.
- Inadequate bone marrow reserve or organ function.
- Uncontrolled pleural effusion or ascites or pericardial effusion.
- Known and untreated, or active central nervous system metastases.
- History of primary or secondary diabetes.
- History of acute or chronic pancreatitis
- Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow the study drug that would preclude adequate absorption of HS-10352.
- History of hypersensitivity to any active or inactive ingredient of HS-10352 or to drugs with a similar chemical structure or class to HS-10352.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
- Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.
Sites / Locations
- SUN YAT-SEN Memorial HospitalRecruiting
- Hunan Cancer HospitalRecruiting
- Fudan University Shanghai Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
HS-10352
Arm Description
There are five escalating dose cohorts
Outcomes
Primary Outcome Measures
Number of subjects with any dose limiting toxicity (DLT)
DLT is defined as one of the following HS-10352 related adverse event (AE) that occurs during the DLT period, excluding AE assessed by investigator exclusively related to subject's underlying disease or medical condition (graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0):
To determine the maximum tolerated dose (MTD)
MTD was defined as the previous dose level at which 2 of 2 subjects or 2 out of 6 subjects experienced a DLT.
Secondary Outcome Measures
Incidence and severity of treatment-emergent adverse events
Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, RECIST1.1, and NCI CTCAE v5.0.
Observed maximum plasma concentration (Cmax) after single dose of HS-10352
In the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10352 on Day 1 to Day 6.
Observed maximum plasma concentration (Cmax ss) after multiple dose of HS-10352
At multiple-dose, Cmax ss will be obtained on Day 1 of dosing in the second 28-Day cycle of therapy.
Time to reach maximum plasma concentration (Tmax) after single dose of HS-10352
In the study of single-dose, Tmax will be obtained following administration of a single oral dose of HS-10352 on Day 1 to Day 6.
Time to reach maximum plasma concentration (Tmax) after multiple dose of HS-10352
At multiple-dose, Tmax will be obtained on Day 1 of dosing in the second 28-Day cycle of therapy.
Apparent terminal half-life (t1/2) after single dose of HS-10352
Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.
Area under plasma concentration versus time curve from zero to the 24-hour sampling time (AUC0-24) after single dose of HS-10352
Area under the plasma concentration versus time curve from time zero to the 24-hour sampling time at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.
Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10352
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-10352
AUC0-∞ was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
To further evaluation of the anti-tumor activity of HS-10352 by assessment of objective response rate (ORR)
Anti-tumor efficacy will be assessed by best radiographic response based on Response Evaluation Criteria in Solid Tumors at baseline (Day -28 to -1). For patients that continue on repeating 28-Day cycles after the primary evaluation period, progression will be assessed after each 8 weeks of therapy. ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.
Disease control rate of HS-10352
Objective response was assessed by RECIST 1.1 thereby to evaluate disease control rate. Disease control was defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 6 weeks).
Deepness of response of HS-10352
Objective response was assessed by RECIST 1.1 thereby to evaluate deepness of response. Depth of response was defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of new lesions, or progression of non-target lesions compared with baseline.
Progression-free survival of HS-10352
Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival. Progression-free survival was defined as the time from date of first dose until the documentation of objective disease progression (PD) or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.
Overall survival of HS-10352
Overall survival was defined as the time from date of first dose until the documentation of death from any cause.
Full Information
NCT ID
NCT04631835
First Posted
November 9, 2020
Last Updated
June 13, 2022
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04631835
Brief Title
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
Official Title
A Phase 1, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10352 in Patients With Locally Advanced or Metastatic Breast Cancer Progressing After Standard Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 8, 2020 (Actual)
Primary Completion Date
April 30, 2023 (Anticipated)
Study Completion Date
August 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110α). In preclinical studies, it demonstrated strong activity against PI3K p110α in vitro and in vivo, and inhibited tumor cell growth. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10352 at single dose and multiple doses.
Detailed Description
This is a phase I, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of single and multiple doses of oral administration of HS-10352 in patients with locally advanced or metastatic breast cancer with hormone receptor (HR) positive and epidermal growth factor receptor 2 (HER2) negative who have progressed following prior therapy. There is a dose-escalation study, which is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose and multiple doses of HS-10352 given once every day (QD). An alternative dosing schedule of twice every day (BID) may be investigated if the drug clearance of HS-10352 is faster than anticipated.
All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with assessments for progression once every 8 weeks, if the product is well tolerated and the subject has stable disease or better. As the disease progresses, survival follow-up is recommended bimonthly.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
dose-escalation, advanced solid tumors, estrogen receptor positive breast cancer, PIK3CA gene mutation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
54 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
HS-10352
Arm Type
Experimental
Arm Description
There are five escalating dose cohorts
Intervention Type
Drug
Intervention Name(s)
HS-10352
Intervention Description
Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Primary Outcome Measure Information:
Title
Number of subjects with any dose limiting toxicity (DLT)
Description
DLT is defined as one of the following HS-10352 related adverse event (AE) that occurs during the DLT period, excluding AE assessed by investigator exclusively related to subject's underlying disease or medical condition (graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0):
Time Frame
From the single dose to the last dose of the first cycle defined as 28 days of multiple dosing (35 days).
Title
To determine the maximum tolerated dose (MTD)
Description
MTD was defined as the previous dose level at which 2 of 2 subjects or 2 out of 6 subjects experienced a DLT.
Time Frame
From the single dose to the last dose of the first cycle defined as 28 days of multiple dosing (35 days).
Secondary Outcome Measure Information:
Title
Incidence and severity of treatment-emergent adverse events
Description
Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, RECIST1.1, and NCI CTCAE v5.0.
Time Frame
From baseline until 28 days after the last dose
Title
Observed maximum plasma concentration (Cmax) after single dose of HS-10352
Description
In the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10352 on Day 1 to Day 6.
Time Frame
From pre-dose to 120 hours after single dose on Day 1
Title
Observed maximum plasma concentration (Cmax ss) after multiple dose of HS-10352
Description
At multiple-dose, Cmax ss will be obtained on Day 1 of dosing in the second 28-Day cycle of therapy.
Time Frame
From pre-dose to 24 hours after the first dose of multiple dosing on Day 1 of the second 28-Day cycle of therapy
Title
Time to reach maximum plasma concentration (Tmax) after single dose of HS-10352
Description
In the study of single-dose, Tmax will be obtained following administration of a single oral dose of HS-10352 on Day 1 to Day 6.
Time Frame
From pre-dose to 120 hours after single dose on Day 1
Title
Time to reach maximum plasma concentration (Tmax) after multiple dose of HS-10352
Description
At multiple-dose, Tmax will be obtained on Day 1 of dosing in the second 28-Day cycle of therapy.
Time Frame
From pre-dose to 24 hours after the first dose of multiple dosing on Day 1 of the second 28-Day cycle of therapy
Title
Apparent terminal half-life (t1/2) after single dose of HS-10352
Description
Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.
Time Frame
From pre-dose to 120 hours after single dose on Day 1
Title
Area under plasma concentration versus time curve from zero to the 24-hour sampling time (AUC0-24) after single dose of HS-10352
Description
Area under the plasma concentration versus time curve from time zero to the 24-hour sampling time at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.
Time Frame
From pre-dose to 24 hours after single dose on Day 1
Title
Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10352
Description
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time Frame
From pre-dose to 120 hours after single dose on Day 1
Title
Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-10352
Description
AUC0-∞ was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time Frame
From pre-dose to 120 hours after single dose on Day 1
Title
To further evaluation of the anti-tumor activity of HS-10352 by assessment of objective response rate (ORR)
Description
Anti-tumor efficacy will be assessed by best radiographic response based on Response Evaluation Criteria in Solid Tumors at baseline (Day -28 to -1). For patients that continue on repeating 28-Day cycles after the primary evaluation period, progression will be assessed after each 8 weeks of therapy. ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.
Time Frame
From the date of first occurrence of complete response (CR) or partial response (PR) on 2 consecutive occasions (≥4 weeks), until the date of disease progression or withdrawal from study, approximately 3 years
Title
Disease control rate of HS-10352
Description
Objective response was assessed by RECIST 1.1 thereby to evaluate disease control rate. Disease control was defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 6 weeks).
Time Frame
From the first occurrence of confirmed CR or PR or SD until the date of disease progression or withdrawal from study, approximately 3 years
Title
Deepness of response of HS-10352
Description
Objective response was assessed by RECIST 1.1 thereby to evaluate deepness of response. Depth of response was defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of new lesions, or progression of non-target lesions compared with baseline.
Time Frame
From the date of enrollment until the date of disease progression or death, approximately 3 years
Title
Progression-free survival of HS-10352
Description
Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival. Progression-free survival was defined as the time from date of first dose until the documentation of objective disease progression (PD) or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.
Time Frame
From the date of enrollment until the date of disease progression or death from any cause, approximately 3 years
Title
Overall survival of HS-10352
Description
Overall survival was defined as the time from date of first dose until the documentation of death from any cause.
Time Frame
From the date of enrollment until the date of death from any cause, approximately 5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men or women aged more than or equal to (≥) 18 years, and less than (<) 75 years.
HR+ HER2- locally advanced or metastatic breast cancer patients confirmed by histology or cytology for who that standard treatment is invalid, unavailable or intolerable.
Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: measurable lesions without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter ≥ 10 mm in the baseline period (in case of lymph nodes, the shortest axis ≥ 15 mm is required)
ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks.
Estimated life expectancy greater than (>) three months.
Females should be using adequate contraceptive measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have evidence of non-childbearing potential.
Sign Informed Consent Form.
Exclusion Criteria:
Treatment with any of the following:
Previous or current treatment with PI3K, AKT or mTOR inhibitors.
Any cytotoxic chemotherapy, investigational agents within 21 days of the first dose of study drug; anticancer drugs which have been received within 14 days before the first administration.
Radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.
Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.
Inadequate bone marrow reserve or organ function.
Uncontrolled pleural effusion or ascites or pericardial effusion.
Known and untreated, or active central nervous system metastases.
History of primary or secondary diabetes.
History of acute or chronic pancreatitis
Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow the study drug that would preclude adequate absorption of HS-10352.
History of hypersensitivity to any active or inactive ingredient of HS-10352 or to drugs with a similar chemical structure or class to HS-10352.
Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xichun Hu
Phone
086-021-64175590
Email
xchu2009@hotmail.com
Facility Information:
Facility Name
SUN YAT-SEN Memorial Hospital
City
Guanzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Herui Yao
First Name & Middle Initial & Last Name & Degree
Herui Yao
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Recruiting
Facility Name
Fudan University Shanghai Cancer Center
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xichun Hu
Phone
086-021-64175590
Email
xchu2009@hotmail.com
First Name & Middle Initial & Last Name & Degree
Xichun Hu
First Name & Middle Initial & Last Name & Degree
Jian zhang
12. IPD Sharing Statement
Learn more about this trial
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
We'll reach out to this number within 24 hrs